MiMedx Group Inc.

Compare

485 Followers

MDXG Stock Chart & Stats

$6.75

$0.12(1.36%)

At close: Jan 08 4:00 PM EST

$6.75

$0.12(1.36%)

Day’s Range― - ―

52-Week Range$5.69 - $10.14

Previous CloseN/A

Volume99.42K

Average Volume (3M)637.30K

Market Cap

$1.02B

Enterprise Value$811.92M

Total Cash (Recent Filing)$118.87M

Total Debt (Recent Filing)$18.46M

Price to Earnings (P/E)31.9

Beta0.81

Next Earnings

Oct 29, 2025

EPS Estimate

0.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding147,959,410

10 Day Avg. Volume474,769

30 Day Avg. Volume637,300

Financial Highlights & Ratios

PEG Ratio-0.84

Price to Book (P/B)7.32

Price to Sales (P/S)4.05

P/FCF Ratio21.92

Enterprise Value/Market Cap0.80

Enterprise Value/Revenue2.23

Enterprise Value/Gross Profit2.74

Enterprise Value/Ebitda16.30

Forecast

1Y Price Target

$12.00

Price Target Upside77.78% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Market PositionMDXG continues to grow versus difficult prior-year comparisons, a testament to the company's execution.

Product SalesMDXG put up another quarter of strong product sales, with $93mn of revenue versus $89.4mn Street, or 7% growth versus 3% expectation.

Strategic InitiativesManagement remains optimistic about current strategic initiatives, with the recent launch of HELIOGEN expected to contribute meaningfully.

Bears Say

Market ChallengesPotential $1.0-1.5bn in Medicare Skin Sub payments still up for grabs.

Reimbursement UncertaintyContinuing reimbursement uncertainty disrupted the business in the physician office setting.

MiMedx Group News

MiMedx announces launch of EPIXPRESS

MiMedx (MDXG) Group announced the launch of EPIXPRESS, the Company’s newest addition to its portfolio of AWC solutions....

23d ago

MDXG

MDXG Upcoming Earnings Report: What to Expect?

MiMedx Group Inc. (MDXG) is scheduled to report 3rd quarter earnings on 10/29/2025, after the market closes. Regarding...

2d ago

MDXG

MiMedx Group Joins Cantor Global Healthcare Conference

MiMedx Group ( ($MDXG) ) just unveiled an announcement. MiMedx Group announced its participation in the Cantor Global...

2M ago

MDXG

MiMedx Group Inc. Reports Record Earnings and Growth

MiMedx Group Inc. (($MDXG)) has held its Q2 earnings call. Read on for the main highlights of the...

3M ago

MDXG

MiMedx price target raised to $12 from $11 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on MiMedx (MDXG) to $12 from $11 and keeps an Overweight...

3M ago

MDXG

ORGO

MiMedx Reports Record Q2 2025 Financial Results

MiMedx Group Inc. ( ($MDXG) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

MDXG

MiMedx Group Reports Record Q2 2025 Financial Results

The latest announcement is out from MiMedx Group ( ($MDXG) ). MiMedx Group announced record financial results for...

3M ago

MDXG

MiMedx sees FY25 revenue up low double-digits percent

Sees FY25 adjusted EBITDA margin above 20%. The company said, “Longer-term, the Company continues to expect to achieve...

3M ago

MDXG

MiMedx reports Q2 EPS 6c, consensus 5c

Reports Q2 revenue $98.61M, consensus $90.79M. Joseph Capper, MiMedx (MDXG) CEO, commented, “We are proud to report on...

3M ago

MDXG

MiMedx announces strategic collaboration with Vaporox

MiMedx (MDXG) Group and Vaporox jointly announced a collaboration, whereby the companies will co-promote and co-market their wound...

3M ago

MDXG

Video: Why Organogenesis And MiMedx Are Sinking Today

The Fly has brought its to-the-moment stock market reporting to YouTube! Listen and subscribe. Published first on TheFly...

4M ago

MDXG

ORGO

MiMedx comments on proposed Medicare reimbursement rule changes

“We welcome and support improvements to Medicare’s reimbursement of skin substitutes across all care settings. The proposed rule,...

4M ago

MDXG

Northland sees ‘key positive’ for MiMedx in CMS rule proposal

Northland analyst Carl Byrnes says the CMS is taking action to curb skin substitute spending with its 2026...

4M ago

MDXG

Organogenesis selloff on CMS proposal ‘may be incorrect,’ says BTIG

BTIG believes the selloff in shares of Organogenesis (ORGO) on the Centers for Medicare and Medicaid Services’ proposed...

4M ago

MDXG

ORGO

MDXG FAQ

What was MiMedx Group Inc.’s price range in the past 12 months?

MiMedx Group Inc. lowest stock price was $5.69 and its highest was $10.14 in the past 12 months.

What is MiMedx Group Inc.’s market cap?

MiMedx Group Inc.’s market cap is $1.02B.

When is MiMedx Group Inc.’s upcoming earnings report date?

MiMedx Group Inc.’s upcoming earnings report date is Oct 29, 2025 which is today.

How were MiMedx Group Inc.’s earnings last quarter?

Currently, no data Available

Is MiMedx Group Inc. overvalued?

According to Wall Street analysts MiMedx Group Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does MiMedx Group Inc. pay dividends?

MiMedx Group Inc. does not currently pay dividends.

What is MiMedx Group Inc.’s EPS estimate?

MiMedx Group Inc.’s EPS estimate is 0.06.

How many shares outstanding does MiMedx Group Inc. have?

MiMedx Group Inc. has 147,959,410 shares outstanding.

What happened to MiMedx Group Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of MiMedx Group Inc.?

Currently, no hedge funds are holding shares in MDXG

MiMedx Group Stock Smart Score

Neutral

Fundamentals

Return on Equity

16.62%

Trailing 12-Months

Asset Growth

26.47%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

MiMedx Group Inc.

MiMedx Group, Inc. (MDXG) is a biotechnology company focused on the development and commercialization of regenerative medicine products based on human amniotic membrane. The company operates primarily in the healthcare sector, specializing in advanced wound care and surgical biologics. MiMedx's core products include allograft tissue products that are used to treat chronic and acute wounds, as well as surgical applications, aimed at enhancing healing and improving patient outcomes.

MiMedx Group (MDXG) Earnings & Revenues

Historic Earnings Reports

MDXG Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a positive outlook due to record revenue and EBITDA, strong segment growth, and strategic product developments. However, there are challenges posed by anticipated changes in Medicare reimbursement and slower than expected clinical trial enrollments.View all MDXG earnings summaries

MDXG Stock 12 Month Forecast

Average Price Target

$12.00

▲(77.78% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","13":"$13","6.25":"$6.25","8.5":"$8.5","10.75":"$10.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,6.25,8.5,10.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.83,7.227692307692307,7.625384615384616,8.023076923076923,8.420769230769231,8.818461538461538,9.216153846153846,9.613846153846154,10.01153846153846,10.409230769230769,10.806923076923077,11.204615384615384,11.602307692307692,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.83,7.227692307692307,7.625384615384616,8.023076923076923,8.420769230769231,8.818461538461538,9.216153846153846,9.613846153846154,10.01153846153846,10.409230769230769,10.806923076923077,11.204615384615384,11.602307692307692,{"y":12,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.83,7.227692307692307,7.625384615384616,8.023076923076923,8.420769230769231,8.818461538461538,9.216153846153846,9.613846153846154,10.01153846153846,10.409230769230769,10.806923076923077,11.204615384615384,11.602307692307692,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.9,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.93,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.38,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.62,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.32,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.39,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.19,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.83,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >